We recently compiled a list of the 14 Worst 52-Week High Stocks to Buy According to Short Sellers. In this article, we are ...

TG Therapeutics yesterday shared new five-year data from the ULTIMATE I & II Phase III trials evaluating Briumvi (ublituximab ...

Continuous treatment with Briumvi (ublituximab) over five years was associated with low rates of relapses and confirmed ...

TG Therapeutics stock popped Wednesday after the company unveiled promising five-year test results for its multiple sclerosis ...

TG Therapeutics (TGTX) presented updated data from the ENHANCE Phase 3b trial evaluating BRIUMVI in patients with relapsing forms of ...

TG Therapeutics announced it updated its data presentations to include details from the ULTIMATE I & II Phase 3 trials, evaluating BRIUMVI. The data showed that continued use of BRIUMVI resulted in an ...

During year 5 of treatment with BRIUMVI the annualized relapse rate was 0.020, equivalent to one relapse occurring every 50 years of patient treatment Overall safety profile of BRIUMVI remained ...

NEW YORK, Sept. 05, 2024 (GLOBE NEWSWIRE) -- (NASDAQ: TGTX), today announced the schedule of upcoming data presentations, highlighting data from both the ULTIMATE I & II ...

Second quarter 2024 U.S. BRIUMVI net revenue of $72.6 million Raising full year 2024 U.S. BRIUMVI net revenue target to approximately $290 - $300 million Cash flow positive for second quarter 2024 ...

Headquartered in Morrisville, NC, the company’s key product, Briumvi, has recently emerged as a notable treatment for Multiple Sclerosis (MS). The company also has other products in its ...

TG Therapeutics' Briumvi shows strong revenue growth, with Q2 2024 revenue up 350% YoY, leading to an upgraded full-year guidance of $290-$300 million. Expansion into CAR-T therapy for autoimmune ...